



# Spermosens publishes annual report for the financial year 2025

Spermosens hereby announces that the annual report for 2025 is now available for download on the company's website, [www.spermosens.com](http://www.spermosens.com). The annual report is also attached as a PDF to this press release. Please note that this version is an English translation of the official Swedish annual report (Årsredovisning) and has not been audited.

As previously announced, the Annual General Meeting will be held on 18 June 2026.

In 2025, Spermosens successfully completed its clinical study at the Reproductive Medicine Center (RMC) in Malmö ahead of schedule. The study demonstrated a statistically significant correlation between sperm binding capacity and fertilisation rates in IVF, confirming the diagnostic value of JUNO-Checked. The core patent was granted in Canada, Mexico, Israel and China, completing the company's global intellectual property through 2039.

Following the clinical study, Spermosens initiated development of JUNO-Checked Generation 3, a system designed for routine use in high-volume clinical laboratories. Generation 3 was completed in April 2026, and a new clinical validation study at RMC is currently underway with early results on track. The company also published a peer-reviewed article on the JUNO-Checked technology and appointed Dr. Jaime Castillo-León as Chief Technology Officer. Memoranda of Understanding were signed with Sapyen in Australia and RSI Reproductive Solutions in the US in January 2026, establishing structured frameworks for potential licence agreements.

Financially, Spermosens ended 2025 without interest-bearing debt and with a substantially stronger cash position than at the start of the year, supported by the SEK 10.8 million strategic investment secured in March 2025 and full exercise of the TO5 warrants in June 2025. In May 2026, the company secured a capital facility of SEK 4.85 million from a group of existing shareholders, subject to shareholder approval, to support continued development and commercialisation of JUNO-Checked and bridge to the TO6 warrants exercisable in November 2026.

With clinical evidence established, Generation 3 under clinical validation, and active partner dialogues across the US, Europe and Asia, Spermosens continues to advance towards licence agreements.

## Auditor's Statement

Forvis Mazars AB has issued an audit report without remarks for the financial year 2025. The auditor highlights a matter of emphasis regarding the Company's liquidity: the Board has secured a capital facility of SEK 4.85 million from existing shareholders, subject to approval by the Annual General Meeting on 18 June 2026. If the financing is not approved, operations may proceed at a slower pace, which could delay commercialisation. The full audit report is translated from Swedish and included in the annual report.

## For further information, please contact:

Tore Duvold, CEO

E-mail: [info@spermosens.com](mailto:info@spermosens.com)

## **About Spermosens AB**

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see [www.spermosens.com](http://www.spermosens.com).